UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024
ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis (AD) has successfully completed Results from the ADESOS study have been selected […]
UNION therapeutics announces publication of results from the OSIRIS Phase 2 study of orismilast in hidradenitis suppurativa in the Journal of the European Academy of Dermatology and Venereology
Orismilast demonstrated clinically relevant improvements in patients with hidradenitis suppurativa (HS), confirming the relevance of orismilast for the treatment of HS 67% of patients completing 16 weeks of treatment achieved […]
UNION therapeutics announces full-year results for 2023
Hellerup, Denmark, February 7, 2024, – UNION therapeutics A/S (“UNION”), a privately held, clinical stage, pharmaceutical development company focused on immunology, announces full-year results for the period January 1 to […]
UNION therapeutics to present at the 42nd Annual J.P. Morgan Healthcare Conference
Hellerup, Denmark, January 5, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION […]
UNION therapeutics announces enrollment of the first patient in the UCORIS Phase 2 IIT study of orismilast in patients with ulcerative colitis
UCORIS is an investigator-initiated, Phase 2 study of orismilast for the treatment of moderate to severe ulcerative colitis (UC) UC is a chronic, inflammatory bowel disease with substantial unmet […]
UNION therapeutics A/S announces new paper on clinical potential of the emerging class of PDE4B/D inhibitors published in journal of Dermatology and Therapy
PDE4-inhibition is a well-established mechanism of action typically used for first line of treatment due to a well-documented safety and tolerability profile As the understanding of PDE4 inhibition has evolved, […]
UNION therapeutics A/S announces publication of results from the IASOS Phase 2b study of orismilast in psoriasis in Journal of the American Academy of Dermatology
In the Phase 2b study, orismilast significantly reduced Psoriasis Area and Severity Index (PASI) compared with placebo from baseline to week 16 39.5% to 49.0% of patients treated with orismilast […]
UNION therapeutics A/S completes patient enrollment for ADESOS Phase 2b study of orismilast in patients with atopic dermatitis
Topline results are expected in the first half of 2024 Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the developed world and a significant unmet […]
UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa
Study demonstrates clinically relevant improvements in patients with hidradenitis suppurativa (HS) receiving 16 weeks of treatment with oral orismilast Study supports the dose-finding results from the recent IASOS Phase 2b […]
UNION therapeutics to present at 4th Annual Dermatology Drug Development Summit Europe
Hellerup, Denmark, May 10, 2023 – UNION therapeutics A/S (UNION), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim […]
